SEC Tracker
Get the app

Indivior Pharmaceuticals INDV

Indivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance

Form
8-K
Filed
Importance
Routine
  • Reports quarterly results (2.02)
  • Makes a Regulation FD disclosure (7.01)

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when Indivior Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Apellis Pharmaceuticals APLS public float $1.8B, Jun 30, 2025
  2. Biocryst Pharmaceuticals BCRX public float $1.9B, Jun 30, 2025
  3. Agios Pharmaceuticals AGIO public float $1.9B, Jun 30, 2025
  4. Amicus Therapeutics FOLD public float $1.7B, Jun 30, 2025
  5. Supernus Pharmaceuticals SUPN public float $1.7B, Jun 30, 2025